1/3/2013

Apeiron Biologics and Evotec entered into a research agreement with the goal of developing immunomodulatory compounds against cancer. Apeiron will share its in vitro and in vivo pharmacology expertise, and Evotec will bring medicinal chemistry and chemical proteomics.

Related Summaries